

REMARKS

Status of Application

Claim 26 has been amended to incorporate all of the limitations of claims 30-31. Claims 28, 30-32, 40-45, 47 and 51 are cancelled hereby without prejudice, estoppel, or waiver.

Applicants respectfully request the entry of the amendment to Claim 26 and the cancellation of claims 28, 30-32, 40-45, 47 and 51.

Allowable Subject Matter


Claim 31 was objected to as being dependent upon a rejected base claim, but allowable if rewritten in independent form including all of the limitations of the base claim and intervening claim(s). Accordingly, Applicants have rewritten the claim as an amendment to claim 26 wherein all of the limitations of claims 30 and 31 are incorporated therein.

CONCLUSION

In view of the foregoing, Applicants believe all claims now pending in this Application are in condition for allowance, and the issuance of a formal Notice of Allowance is respectfully requested.

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 650.283.6790.

Respectfully submitted,



Michael J. Mazza
Attorney for Applicants
Reg. No. 30,775

Novartis
Corporate Intellectual Property
One Health Plaza, Building 430
East Hanover, NJ 07936-1080
(510) 923-4298

Date: August 23, 2010